CSF pleocytosis is not always present in herpes simplex virus infection of the nervous system  by Saraya, A. et al.
al of I
T
F
S
D
T
R
C
i
A
Z
c
h
i
w
a
c
K
O
w
1
c
C
e
e
8
a
c
c
p
o
w
T
(
w
w
2
g
p
v
a
e
h15th ICID Abstracts / International Journ
ype: Poster Presentation
inal Abstract Number: 40.088
ession: Virology and Viral Infections (Non-HIV)
ate: Thursday, June 14, 2012
ime: 12:45-14:15
oom: Poster & Exhibition Area
SF pleocytosis is not always present in herpes simplex virus
nfection of the nervous system
. Saraya ∗, H. Wilde, T. Hemachudha
WHO Collaborating Centre for Research and Training on Viral
oonoses, Bangkok, Thailand
Background: Herpes simplex virus (HSV) infection can involve
entral and peripheral nervous system. Absence of CSF pleocytosis
as been described which can lure physicians to look for non-
nfectious causes. The objective was to determine the extent to
hich normal CSF cells could be found in neurological infection
ssociated with HSV.
Methods: We studied patients with HSV associated neurologi-
al infections whose diagnosis was conﬁrmed by PCR, admitted to
ing Chulalongkorn Memorial Hospital between January 2002 and
ctober 2010.
Results: Among 109 patients with neurological infections, HSV
as found in 34 (31%). Among 29, where we had complete records,
6 had encephalitis, 8 had meningitis, 2 myelitis, 2 myeloradi-
ulitis and 1 presented with radiculitis. Twenty-eight patients had
SF collected at initial and subsequent visits. Four patients with
ncephalitis, 2 myeloradiculitis, 1 myelitis and 1 radiculitis had no
levatedCSF cells. Fourhadnormal CSFprotein levels. Sevenamong
had CSF examinations within 10 days after onset of illness (aver-
ge of 3 days). Three of 4 patients with HIV infection had low CD4
ounts (<200cells). One of these had WBC of 3,150cells. CSF white
ell counts remained normal in 5 of 6 who had repeated lumbar
unctures. Among the CSF pleocytosis group of 20 and a cell range
f 6-730 CSF cells (mean 105), none had HIV infection. This group
as composed of 11 encephalitis, 8 meningitis, 1 myelitis cases.
hree in the normo-cellular CSF group had unremarkable CT brains
2withHIV) and3hadabnormalMRIs (1brain and2 spinal cords) (1
ith HIV). One CT brain and 2 MRI brains in the pleocytosis group
ere normal (MRI brains were abnormal in 10 and CT brains in
). Six of 8 in the normo-cellular and 9 of 20 in the pleocytosis
roups could resume daily life activities after recovery. Two in the
leocytosis group completely recovered and 2 died.
Conclusion: Normal CSF cell counts in HSV infection of the ner-
ous system is not uncommon and can be seen in normal as well
s HIV infected patients. Clinicians should not exclude infection
specially with HSV based on absence of CSF pleocytosis.
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Antiviral drug-associated potential vaccine-escape hepatitis B
virus mutants in Turkish patients with chronic hepatitis B
M. Sayan ∗, S.C. Akhan
Kocaeli University, Izmit, Kocaeli, Turkey
Background: The hepatitis B virus (HBV) polymerase (pol) gene
completely overlaps with the envelope (S) gene. Mutations in the
pol gene of HBV, either from selection of primary or secondary
resistance mutations, typically result in changes in the overlapping
hepatitis B surface antigen (HBsAg). Recent studies have con-
ferred a new acronym to these HBV pol/ S gene overlap mutants:
ADAPVEMs, for antiviral drug-associated potential vaccine-escape
mutants. The present study aimed to assess the prevalence and
pattern of ADAPVEMs in Turkish patients with chronic hepatitis
B (CHB).
Methods: The investigation was conducted between March
2007 and July 2010 and involved a total of 442 patients. These
patients were in the following phases of HBV infection: immune
tolerant (n = 50), immune reactive (n = 37), inactive carrier (n =
90), HBeAg-negative CHB (n = 217), and HBsAg-negative (n = 12),
or were hemodialysis patients (n = 36). One hundred eighty-six
patients were receiving nucleos(t)ide analogue (NUC) therapy and
256 patients had treatment-naıve CHB.
Results: Seven types of ADAPVEM were detected in the
total CHB patients: rtM204 V/sI195 M, rtM204I/sW196S,
rtM204I/sW196L, rtV173L/sE164D, rtA181T/sW172*,
rtA181T/sW172L, and rtA181 V/sL173F. The ADAPVEMs were
associated with lamivudine, telbivudine, and adefovir. The preva-
lence of ADAPVEMs in all CHB patients was found to be 10%
(46/442). The difference in the prevalence of ADAPVEMs across
the different CHB clinical phases was not signiﬁcant (Pearson
Chi-square, p = 0.112). The prevalence of ADAPVEMs was 24%
(44/186) in those undergoing NUC therapy and 0.7% (2/256) in the
treatment-naıve group; this difference was signiﬁcant (Pearson
Chi-square, p = 0.00).
Conclusion: We determined the prevalence and pattern of
ADAPVEMs in Turkish patients in the different phases of CHB. Pre-
ferred drugs in Turkey, such as lamivudine, have the potential
to cause the emergence of ADAPVEMs, with the possibility that
these will spread to both individuals immunized with the hepati-
tis B vaccine and nonimmunized individuals. ADAPVEMs should be
monitored in infected and treated patients and their public health
risks assessed.
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